Clinical Trial Update: Safety of TKI258 in Advanced/Metastatic Melanoma Subjects [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting safety data for TKI258 in advanced/metastatic melanoma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TKI258

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED